TY - JOUR
T1 - Real-world management of trabectedin/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: A national survey
AU - Ferrandina, Maria Gabriella
AU - Amadio, Giulia
AU - Paris, Ida
AU - Distefano, Mariagrazia
AU - Palluzzi, Eleonora
AU - De Vincenzo, Rosa Pasqualina
AU - Ricci, Caterina
AU - Scambia, Giovanni
PY - 2017
Y1 - 2017
N2 - Background Trabectedin (T) plus pegylated liposomal doxorubicin (PLD) is approved for treatment of platinum-sensitive recurrent ovarian cancer (ROC). Despite the recommendations and guidelines, variations in managing T/PLD administration in routine clinical practice cannot be excluded. We aimed at setting up an Italian survey collecting data about management of T/PLD administration in ROC patients. Methods We carried out the development of a questionnaire-based survey on routine clinical practice in the management of ROC patients administered T/PLD. The survey registered the physicians' approach to modification/discontinuation of treatment, type of modifications, reasons why, and so on. The survey was transmitted to medical oncologists and gynecologic oncologists practicing in national centers/institutions. Results Fifty-eight Italian centers/institutions returned the compiled questionnaire; participants practiced at community cancer centers or hospitals (56.9%), academic institutions (36.2%), and other settings (private clinics, etc) (6.9%). There was no statistically significant difference in the distribution of practice setting according to geographic areas. Most responders were medical oncologists (84.5%) and were members (82.8%) of at least 1 scientific society or cooperative group. Almost 31.5% of responders reported interruption of the whole treatment, mostly because of toxicity (41.2%), followed by patients' choice (29.4%), or achievement of clinical benefit (23.5%). Dose reduction was referred by 47.4% of responders. Reduction of dose for both drugs was referred by 88.5% of responders, and the extent of dose reduction ranged between 10% and 30%. Conclusions This survey highlights the gaps in transposing evidence-based or consensus guidelines in the real-world management of T/PLD administration; these findings could be useful in order to focus the attention on specific knowledge and/or experience gaps and plan pertinent educational programs.
AB - Background Trabectedin (T) plus pegylated liposomal doxorubicin (PLD) is approved for treatment of platinum-sensitive recurrent ovarian cancer (ROC). Despite the recommendations and guidelines, variations in managing T/PLD administration in routine clinical practice cannot be excluded. We aimed at setting up an Italian survey collecting data about management of T/PLD administration in ROC patients. Methods We carried out the development of a questionnaire-based survey on routine clinical practice in the management of ROC patients administered T/PLD. The survey registered the physicians' approach to modification/discontinuation of treatment, type of modifications, reasons why, and so on. The survey was transmitted to medical oncologists and gynecologic oncologists practicing in national centers/institutions. Results Fifty-eight Italian centers/institutions returned the compiled questionnaire; participants practiced at community cancer centers or hospitals (56.9%), academic institutions (36.2%), and other settings (private clinics, etc) (6.9%). There was no statistically significant difference in the distribution of practice setting according to geographic areas. Most responders were medical oncologists (84.5%) and were members (82.8%) of at least 1 scientific society or cooperative group. Almost 31.5% of responders reported interruption of the whole treatment, mostly because of toxicity (41.2%), followed by patients' choice (29.4%), or achievement of clinical benefit (23.5%). Dose reduction was referred by 47.4% of responders. Reduction of dose for both drugs was referred by 88.5% of responders, and the extent of dose reduction ranged between 10% and 30%. Conclusions This survey highlights the gaps in transposing evidence-based or consensus guidelines in the real-world management of T/PLD administration; these findings could be useful in order to focus the attention on specific knowledge and/or experience gaps and plan pertinent educational programs.
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Dioxoles
KW - Doxorubicin
KW - Female
KW - Humans
KW - Italy
KW - Management of adverse effect
KW - Neoplasm Recurrence, Local
KW - Obstetrics and Gynecology
KW - Oncologists
KW - Oncology
KW - Ovarian Neoplasms
KW - Pegylated liposomal doxorubicin
KW - Polyethylene Glycols
KW - Practice Patterns, Physicians'
KW - Recurrent ovarian cancer
KW - Survey
KW - Surveys and Questionnaires
KW - Tetrahydroisoquinolines
KW - Trabectedin
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Dioxoles
KW - Doxorubicin
KW - Female
KW - Humans
KW - Italy
KW - Management of adverse effect
KW - Neoplasm Recurrence, Local
KW - Obstetrics and Gynecology
KW - Oncologists
KW - Oncology
KW - Ovarian Neoplasms
KW - Pegylated liposomal doxorubicin
KW - Polyethylene Glycols
KW - Practice Patterns, Physicians'
KW - Recurrent ovarian cancer
KW - Survey
KW - Surveys and Questionnaires
KW - Tetrahydroisoquinolines
KW - Trabectedin
UR - http://hdl.handle.net/10807/111685
UR - http://journals.lww.com/ijgc/pages/default.aspx
U2 - 10.1097/IGC.0000000000001058
DO - 10.1097/IGC.0000000000001058
M3 - Article
SN - 1048-891X
VL - 27
SP - 1141
EP - 1148
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
ER -